{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:14:44Z","timestamp":1788480884542,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.pnpbp.2025.111495","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:46:27Z","timestamp":1757605587000},"page":"111495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Augmentation with glutamatergic modulators for schizophrenia: A network meta-analysis"],"prefix":"10.1016","volume":"142","author":[{"given":"Chun-Wei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Yi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chih Meg","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2025.111495_bb0005","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/0269881118822157","article-title":"Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials","volume":"33","author":"Chang","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881120908016","article-title":"Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials","volume":"34","author":"Chang","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1192\/bjp.bp.111.107359","article-title":"Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy","volume":"203","author":"Choi","year":"2013","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0020","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehu424","article-title":"Systematic reviews and meta-analyses of randomized trials: principles and pitfalls","volume":"35","author":"da Costa","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0025","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1111\/bph.13919","article-title":"Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research: glutamate cognition and networks","volume":"174","author":"Dauvermann","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0030","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1080\/14656566.2022.2145884","article-title":"Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia","volume":"23","author":"de Bartolomeis","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102473","article-title":"Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis","volume":"69","author":"Etchecopar-Etchart","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0045","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0055","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/0269881120965937","article-title":"Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: a meta-analysis of randomised, placebo-controlled trials","volume":"35","author":"Goh","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0060","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/schbul\/sbs010","article-title":"NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia","volume":"38","author":"Gonzalez-Burgos","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuroscience.2008.05.029","article-title":"Surface trafficking of N-methyl-D-aspartate receptors: physiological and pathological perspectives","volume":"158","author":"Groc","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0075","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2021"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0080","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0085","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mp.2015.68","article-title":"Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials","volume":"20","author":"Iwata","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0090","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0095","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1523\/JNEUROSCI.4129-11.2012","article-title":"Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons","volume":"32","author":"Kaufman","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0100","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/biom10081134","article-title":"Is memantine effective as an NMDA-receptor antagonist in adjunctive therapy for schizophrenia?","volume":"10","author":"Kikuchi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0105","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jpsychires.2013.04.013","article-title":"NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials","volume":"47","author":"Kishi","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0110","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00213-017-4616-7","article-title":"Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis","volume":"234","author":"Kishi","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/pcn.13502","article-title":"N-acetylcysteine for schizophrenia: a systematic review and meta-analysis","volume":"77","author":"Kishi","year":"2023","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coph.2014.01.001","article-title":"Schizophrenia: from dopaminergic to glutamatergic interventions","volume":"14","author":"Laruelle","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1370431","article-title":"Effects of sodium benzoate on cognitive function in neuropsychiatric disorders: a systematic review and meta-analysis","volume":"15","author":"Liang","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/15622975.2015.1117654","article-title":"Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial","volume":"18","author":"Lin","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17425255.2021.1885648","article-title":"Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Marchi","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0155","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0160","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0165","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst. Rev."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157015908783769671","article-title":"Pharmacodynamics of memantine: an update","volume":"6","author":"Rammes","year":"2008","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00406-014-0528-2","article-title":"What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial","volume":"265","author":"Schennach","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102947","article-title":"Efficacy and safety of add-on sodium benzoate, a D-amino acid oxidase inhibitor, in treatment of schizophrenia: a systematic review and meta-analysis","volume":"68","author":"Seetharam","year":"2022","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","article-title":"Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a \u201ccentral hub\u201d in schizophrenia pathophysiology?","volume":"176","author":"Steullet","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0200","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/138161210790361452","article-title":"Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis","volume":"16","author":"Tsai","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0210","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jclinepi.2005.08.017","article-title":"A systematic review identifies a lack of standardization in methods for handling missing variance data","volume":"59","author":"Wiebe","year":"2006","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103375","article-title":"Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment","volume":"79","author":"Yeh","year":"2023","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0220","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0004867419893439","article-title":"Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia","volume":"54","author":"Yolland","year":"2020","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111495_bb0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/1028415X.2018.1478766","article-title":"Improvement of cognitive function in schizophrenia with N-acetylcysteine: a theoretical review","volume":"23","author":"Yolland","year":"2020","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111495_bb0230","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1017\/S0033291717001271","article-title":"Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"48","author":"Zheng","year":"2018","journal-title":"Psychol. Med."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625002490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625002490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:20:41Z","timestamp":1762266041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625002490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"alternative-id":["S0278584625002490"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111495","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmentation with glutamatergic modulators for schizophrenia: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111495"}}